Search results
CVS COVID-19 Vaccine Near Columbus OH
www.cvs.comPharmacy LocationBy appointment only3307 East Broad Street(614) 235-8605591 East Livingston(614) 464-24801400 Parsons Avenue(614) 449-93993424 S High Street(614) 491-81374199 Morse Xing(614) 471-32641892 N High Street(614) 298-80513355 East Livingston Avenue(614) 237-3737CEPI 2.0 and the 100 Days Mission. CEPI’s 2022-2026 strategy, known as CEPI 2.0, will help Prepare, Transform, and Connect the world so that it can respond to the next Disease X threat with a new vaccine in just three months. Read more
- Who We Are
CEPI’s 2022-2026 plan, known as CEPI 2.0, will help the...
- Priority Diseases
CEPI’s priority pathogens include Chikungunya, COVID-19,...
- Careers
To learn more and hear directly from the people who drive...
- Contact
CEPI is keen to discuss potential involvement with...
- Why We Exist
That vaccine was shown to have 100% efficacy, suggesting...
- Support CEPI
CEPI partners with vaccine developers, manufacturers,...
- Our Portfolio
CEPI is providing up to US $25 million to advance...
- Covax
Seven CEPI-backed vaccines have been approved for use either...
- 100 Days
CEPI’s 2022-2026 strategy, known as CEPI 2.0, will help...
- Platform Technology
It also co-led COVAX, the global initiative to deliver fair...
- Who We Are
1 day ago · CEPI 28th May 2024. BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for Africa. CEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing needs of African ...
Jul 5, 2022 · CEPI will provide up to US $30 million to support the development of the vaccine through Phase I trials, including preclinical work, with the aim to establish first-in-human clinical proof of concept for the vaccine. The funding will also support the design of the vaccine and regulatory activities.
CEPI outlined its projects to update CEPI priorities for establishment of technical and regulatory pathways for vaccine development, develop sustainable manufacturing solutions for vaccine candidates nearing completion, and create investigatory stockpiles of its vaccine candidates for use in emergency situations.